Onward Medical N.V. Net Assets
Onward Medical N.V. net assets. Based on the latest financial reports, Onward Medical N.V. (ONWD) has net assets worth €55.32 Million EUR (≈ $64.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€84.55 Million ≈ $98.85 Million USD) and total liabilities (€29.24 Million ≈ $34.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ONWD net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €55.32 Million |
| % of Total Assets | 65.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.1% |
| 10-Year Change | N/A |
| Growth Volatility | 90.12 |
Net Assets of Onward Medical N.V. (2017–2025)
Net assets of Onward Medical N.V. from 2017 to 2025. This chart illustrates how Onward Medical N.V.'s net assets have evolved over time, based on quarterly financial data. See Onward Medical N.V. balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Onward Medical N.V. (2017–2025)
The table below shows the annual net assets of Onward Medical N.V. from 2017 to 2025. For live market cap and overall valuation, see Onward Medical N.V. (ONWD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €55.32 Million ≈ $64.67 Million |
+15.11% |
| 2024-12-31 | €48.05 Million ≈ $56.18 Million |
+167.99% |
| 2023-12-31 | €17.93 Million ≈ $20.96 Million |
-65.93% |
| 2022-12-31 | €52.63 Million ≈ $61.53 Million |
-36.35% |
| 2021-12-31 | €82.68 Million ≈ $96.67 Million |
+357.62% |
| 2020-12-31 | €-32.09 Million ≈ $-37.52 Million |
-115.07% |
| 2019-12-31 | €-14.92 Million ≈ $-17.45 Million |
-45.32% |
| 2018-12-31 | €-10.27 Million ≈ $-12.01 Million |
-163.85% |
| 2017-12-31 | €-3.89 Million ≈ $-4.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Onward Medical N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21303400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Onward Medical N.V. Net Assets Breakdown (December 2025)
Onward Medical N.V. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €6.72 Million | 12.15% |
| Other Components | €271.15 Million | 490.19% |
| Total Equity | €55.32 Million | 100.00% |
Onward Medical N.V. Competitors by Market Cap
The table below lists competitors of Onward Medical N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wasko S.A.
WAR:WAS
|
$153.65 Million |
|
Donga Geologic
KO:028100
|
$153.65 Million |
|
SFP Tech Holdings Bhd
KLSE:0251
|
$153.65 Million |
|
Curexo Inc
KQ:060280
|
$153.72 Million |
|
Black Spade Acquisition II Co
NASDAQ:BSII
|
$153.61 Million |
|
Starpharma Holdings Ltd
AU:SPL
|
$153.58 Million |
|
TONT
NYSE MKT:TONT
|
$153.49 Million |
|
BriQ Properties Real Estate Investment Company
AT:BRIQ
|
$153.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onward Medical N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,054,000 to 55,316,000, a change of 7,262,000 (15.1%).
- Net loss of 41,787,000 reduced equity.
- New share issuances of 51,187,000 increased equity.
- Other comprehensive income decreased equity by 6,770,000.
- Other factors increased equity by 4,632,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-41.79 Million | -75.54% |
| Share Issuances | €51.19 Million | +92.54% |
| Other Comprehensive Income | €-6.77 Million | -12.24% |
| Other Changes | €4.63 Million | +8.37% |
| Total Change | €- | 15.11% |
Book Value vs Market Value Analysis
This analysis compares Onward Medical N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.53x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €-0.49 | €1.89 | x |
| 2019-12-31 | €-0.72 | €1.89 | x |
| 2020-12-31 | €-1.54 | €1.89 | x |
| 2021-12-31 | €2.74 | €1.89 | x |
| 2022-12-31 | €1.74 | €1.89 | x |
| 2023-12-31 | €0.59 | €1.89 | x |
| 2024-12-31 | €1.08 | €1.89 | x |
| 2025-12-31 | €1.24 | €1.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Onward Medical N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1105.48%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.53x
- Recent ROE (-75.54%) is below the historical average (-56.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -2091.14% | 0.05x | 0.00x | €-8.89 Million |
| 2019 | 0.00% | -2433.75% | 0.02x | 0.00x | €-11.99 Million |
| 2020 | 0.00% | -3450.69% | 0.04x | 0.00x | €-16.80 Million |
| 2021 | -41.50% | -2814.93% | 0.01x | 1.27x | €-42.58 Million |
| 2022 | -62.27% | -1578.61% | 0.03x | 1.46x | €-38.04 Million |
| 2023 | -201.78% | -6800.94% | 0.01x | 2.43x | €-37.97 Million |
| 2024 | -74.34% | -46396.10% | 0.00x | 1.62x | €-40.53 Million |
| 2025 | -75.54% | -1105.48% | 0.04x | 1.53x | €-47.32 Million |
Industry Comparison
This section compares Onward Medical N.V.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,134,363,934
- Average return on equity (ROE) among peers: -16.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onward Medical N.V. (ONWD) | €55.32 Million | 0.00% | 0.53x | $153.63 Million |
| Argen-X (ARGX) | $66.65 Million | -33.73% | 0.67x | $47.46 Billion |
| BioSenic S.A. (BIOS) | $-6.76 Million | 0.00% | 0.00x | $1.57 Million |
| Celyad SA (CYAD) | $90.88 Million | -25.97% | 0.53x | $8.95 Million |
| Hyloris Developmentsen Sa (HYL) | $39.07 Million | -39.37% | 0.22x | $123.41 Million |
| Oxurion NV (OXUR) | $35.28 Million | -28.73% | 0.06x | $62.21K |
| Tubize-Fin (TUB) | $443.43 Million | 0.00% | 0.18x | $7.82 Billion |
| UCB SA (UCB) | $7.27 Billion | 10.07% | 0.83x | $38.48 Billion |
About Onward Medical N.V.
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more